



BioLayer Corporation Limited

03 July 2007

BioLayer and The University of Queensland enter Joint Research Collaboration

Brisbane based material sciences company BioLayer Corporation Limited (ASX:BLS) today announced it has signed a joint research agreement with The University of Queensland's Institute for Molecular Bioscience (IMB).

The project, entitled "Smarter Diagnostics through Selective Chemical Tagging", is sponsored under Queensland's Smart State Research and Industry Partner program to the tune of \$400,000 and will run for 2 years.

It will be based on BioLayer's existing technology in binding, orienting and protecting antibodies bound to immunoassay surfaces but applied to labeling secondary antibodies or other proteins in solution with colorimetric or fluorescent tags. This is expected to increase the signal generated in the immunoassay and provide even greater sensitivity than was previously possible, while also improving reproducibility.

BioLayer will commercialise the newly developed technology through established links with multinational life science, biotechnology and *in vitro* diagnostic companies by incorporating it into clinical diagnostic kits destined for the global USD 6.0b immunoassay market.

"This collaboration will bring together the chemistry/biology expertise of the IMB with BioLayer's material sciences R&D and commercialization capabilities" said David Beins, BioLayer's CEO and Managing Director.

"It will provide a highly effective two-pronged approach to solving the assay sensitivity problems experienced by our customers and in fact has a multiplier effect if we use it in combination with the sensitivity improvements already shown with our surface coating technologies alone" he said.

The technology will first be applied to the creation of a new generation test for Troponin I, an important biomarker of cardiac disease with high clinical demand for greater sensitivity to assist in risk assessment and early diagnosis.

BioLayer Corporation Limited ABN 75 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113
Phone 07 3219 0085 Fax 07 3219 0553 Email contact@biolayercorp.com
Web www.biolayercorp.com



BioLayer Corporation Limited

Other targets to be developed over time will enable a response to growing market needs for more powerful new diagnostics to better detect disease-causing agents and other biomarkers of human disease, including tests that predict disease susceptibility for use in preventative medicine.

About BioLayer:

BioLayer Corporation is an Australian material sciences company specializing in the design and assembly of multi-component coatings for the solid phase of immunoassay and bioseparations. BioLayer's proprietary coatings bind, orient and protect proteins such as antibodies in specific ways that enhance functionality. In the case of immunoassay this results in dramatically improved performance like better sensitivity, and cost savings like batch-to-batch reproducibility. In bioseparations it means a totally synthetic and robust surface that specifically and reversibly binds any target protein. BioLayer works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit www.bio-layer.com.

BioLayer Corporation Limited ABN 75 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113
Phone 07 3219 0085 Fax 07 3219 0553 Email contact@biolayercorp.com
Web www.biolayercorp.com